Deterioration free discharge comparison of andexanet-alfa and prothrombin complex concentrates (PCC) for reversal of factor Xa inhibitor associated bleeds
Journal of Thrombosis and Thrombolysis · 2023
DOI: 10.1007/s11239-023-02840-8 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Thrombosis and Thrombolysis, 2023. Verfasst von Jason J Keinath und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Henry Ford Health Henry Ford Hospital, 2799 W. Grand Blvd., Detroit, MI, 48202, USA. jkeinat1@hfhs.org. Hauptthemen laut MEDLINE: Factor Xa Inhibitors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Given the paucity of comparative efficacy data and the difference in cost between andexanet-alfa and prothrombin complex concentrates (PCC), debates continue regarding optimal cost-effective therapy for patients who present with major bleeding associated with oral factor Xa inhibitors. Available literature comparing the cost-effectiveness of the reversal agents is limited, and the large difference in price between therapy options has led many health systems to exclude andexanet-alfa from their formularies. To evaluate the clinical outcomes and cost of PCC compared to andexanet-alfa for patients with factor Xa inhibitor associated bleeds. We performed a quasi-experimental, single health system study of patients treated with PCC or andexanet-alfa from March 2014 to April 2021. Deterioration-free discharge, thrombotic events, length of stay, discharge disposition, and cost were reported. 170 patients were included in the PCC group and 170 patients were included in the andexanet-alfa group. Deterioration-free discharge was achieved in 66.5% of PCC-treated patients compared to 69.4% in the andexanet alfa-treated patients. 31.8% of PCC-treated patients were discharged home compared to 30.6% in the andexanet alfa-treated patients. The cost per deterioration-free discharge was $20,773.62 versus $5230.32 in the andexanet alfa and 4 F-PCC group, respectively. Among patients that experienced a bleed while taking a factor Xa inhibitor, there was no difference in clinical outcomes for patients treated with andexanet-alfa compared to PCC. Although there was no difference in the clinical outcomes, there was a significant difference in cost with andexanet-alfa costing approximately four times as much as PCC per deterioration-free discharge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Henry Ford Health Henry Ford Hospital, 2799 W. Grand Blvd., Detroit, MI, 48202, USA. jkeinat1@hfhs.org.
- Syneos Health, Morrisville, USA.
- Department of Pharmacy, Indiana University Health Methodist Hospital, Indianapolis, IN, USA.
- Department of Pharmacy, Henry Ford Health Wyandotte Hospital, Wyandotte, MI, USA.
- Department of Pharmacy, Henry Ford Health Henry Ford Hospital, 2799 W. Grand Blvd., Detroit, MI, 48202, USA.
Zitieren
APA
Keinath, J. J., Lekura, J., Hauser, C. D., Bajwa, M. K., Bloome, M. E., Kalus, J. S., & Jones, M. C. (2023). Deterioration free discharge comparison of andexanet-alfa and prothrombin complex concentrates (PCC) for reversal of factor Xa inhibitor associated bleeds. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-023-02840-8
Vancouver
Keinath JJ, Lekura J, Hauser CD, Bajwa MK, Bloome ME, Kalus JS, et al. Deterioration free discharge comparison of andexanet-alfa and prothrombin complex concentrates (PCC) for reversal of factor Xa inhibitor associated bleeds. Journal of Thrombosis and Thrombolysis. 2023. doi:10.1007/s11239-023-02840-8
BibTeX
@article{Keinath2023,
author = {Keinath, Jason J and Lekura, Jona and Hauser, Christian D and Bajwa, Manisha K and Bloome, Michael E and Kalus, James S and Jones, Mathew C},
title = {Deterioration free discharge comparison of andexanet-alfa and prothrombin complex concentrates (PCC) for reversal of factor Xa inhibitor associated bleeds},
journal = {Journal of Thrombosis and Thrombolysis},
year = {2023},
doi = {10.1007/s11239-023-02840-8}
}
EUVIMED